CorFlow Therapeutics is excited to announce a successful funding round, having raised an impressive $48.5 million to further its pioneering work in microvascular diagnostics and therapies. Founded in 2016 in Baar, Switzerland, CorFlow is on a mission to enhance cardiac care by addressing the critical issue of microvascular dysfunction and obstruction, which often goes undetected during traditional percutaneous coronary interventions (PCI). This innovative funding will accelerate the development of our groundbreaking diagnostic system designed to reveal microvascular obstruction (MVO) in real-time within the cath lab, enabling clinicians to proactively manage patient care. Currently under ongoing clinical studies, this investigational system aims to improve the efficacy and safety of cardiac interventions, ultimately contributing to better patient outcomes. Led by CEO Paul Mead, who has nearly two decades of medtech experience at Medtronic, and Chairman Rick Geoffrion of Cyrano Therapeutics, the company is committed to transforming the future of cardiology and beyond. CorFlow’s strategic vision is not only to lead the market in microvascular blood flow solutions but also to uphold values centered on quality, ethical standards, and inclusivity—all while addressing significant environmental, social, and governance goals. This latest funding round, bolstered by a combination of angel investors, venture capital, and Swiss government grants, positions CorFlow for an impactful Series B round targeted for later this year, reinforcing our relentless pursuit to meet unmet medical needs and extend the quality of human life. We’re thrilled about the next chapter in our journey and look forward to sharing our advancements with the medical community and patients alike.
CorFlow Therapeutics Secures 48.5M in Series B Funding to Revolutionize Microvascular Diagnosis and Treatment: Leading the Way in Cardiology Innovation
Get the full CorFlow Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
YIRUI Pharmaceutical Technology
At YIRUI Pharmaceutical Technology, we are committed to providing innovative therapeutic solutions, which are anticipated to improve health of patients with serious disease and fill the urgent unmet medical needs. YIRUI Pharmaceutical Technology was founded in June 2018. We are currently in a period of rapid growth. With an extraordinarily talented team consisting of experienced pharmaceutical scientists, physicians and executives, we have identified and optimized a number of lead compounds against the first-in-class targets, which show high therapeutic potential for the treatment and prevention of chronic skin diseases, autoimmune disorders, diabetes complications and other serious diseases. By focusing on small molecule drugs development and patient-centered research, our perspective is to bring more and more safe, effective and affordable drugs with high quality to the largest number of patients.
$14.7M Series a
today
SPARK Biopharma, Inc.
We Provide Small-molecule Therapeutics using Phenotypic Discovery for Improving Human Health.
$21.0M Series a
today
CogitoAI.ai
Cogito AI is all about making Enterprise AI profitable for your company. Cogito AI is developing a next-generation Enterprise AI platform that helps companies in knowledge intensive industries, such as healthcare, life sciences, financial services, professional services and technology, to roll out business impactful Gen AI agents and use cases quickly and effectively. Our goal is to boost revenues, streamline efficiency and improve customer and employee satisfaction.
$3.5M Seed
today
Immunocan
Founded in 2020, Shanghai Immunocan Biotech Co., Ltd. is a biotechnology company dedicated to building antibody drug discovery platforms using innovative gene editing technology. Our goal is to empower global antibody drug R&D with proprietary gene-edited animal platform generating human and alpaca antibody, suitable for different drug discovery scenarios.
$37.0M Series a
today
Layup Parts
Layup manufactures composite parts and the tooling to make those parts. We are developing tools that will put parts in our customers hands faster than has previously been possible. Our goal is to ship parts faster than our competition can return a quote.
$42.0M Series a
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  MJOLNIR SPACEWORKS Japan | Series b | $11.1M | today |
| 2 |  Advanced NanoTherapies, Inc United States | Series b | $31.0M | today |
| 3 |  FRANQ The Netherlands | Series b | $12.4M | today |
| 4 |  Tripo AI United States | Series b | $200.0M | today |
| 5 |  Saris AI | Series b | $35.0M | 1d ago |